The purpose of this study is to assess severity of illness in schizophrenia patients in routine clinical practice at the time of entry in the study and after the treatment with Seroquel XR for 8 weeks.

PLEASE NOTE: Seroquel SR and Seroquel XR refer to the same formulation. The SR designation was changed to XR after consultation with FDA.

Inclusion Criteria:

• Adult patients with Schizophrenia prescribed on Seroquel XR according to the approved product information before inclusion in this non-interventional study
• Signed and dated Patient Informed Consent (ICF)

Exclusion Criteria:

• Hypersensitivity to the active substance or to any of the excipients of Seroquel XR

primary care clinics